

FDA's First Biosimilar Approval Greeted with Optimism; Naming, Pricing Still Issues

March 9, 2015

ATTORNEYS

Ropka, PhD, Stacie

John Aquino

Bloomberg BNA Life Science's Law & Industry Report

Axinn Counsel Stacie Ropka was quoted in the Bloomberg BNA Life Science's Law & Industry Report article, "FDA's First Biosimilar Approval Greeted with Optimism; Naming, Pricing Still Issues."

[Click here to access the article.](#)